Patients receiving B-cell-depleting therapies (BCDT) are at an increased risk for severe COVID-19. Passive antibody therapy (PAT). including COVID-19 convalescent plasma (CCP) and monoclonal antibodies (mAb). may be an effective treatment in this population. https://www.spidertattooz.com/NYX-Total-Control-Drop-Foundation-Brush-PROB22-p11165/